Literature DB >> 7135359

Substitution therapy with an antithrombin III concentrate in shock and DIC.

B Blauhut, S Necek, H Vinazzer, H Bergmann.   

Abstract

In 15 patients admitted to the Intensive Care Unit for shock and with signs of DIC, Antithrombin III (AT III) was substituted. Immediately after the first blood sampling, 1,000 units of AT III was given. This was followed by 500 units AT III after 24 h and after 48 h. A continuous dose of heparin of between 250 and 500 I.U./h was simultaneously given. The following results were obtained: The activity of AT III on admission of 63 +/- 19% increased to 83 +/- 17% 30 min after the initial substitution. There was a clear difference between the recovery of the substituted AT III in acute DIC and in patients in a steady state. AT III recovered in circulation was 47 +/- 15% in the former group but 83 +/- 16% in the latter cases. One unit of AT III per kg body weight increased AT III activity in circulation by 1% in acute DIC but by 1.8% in a steady state. The average half life of the substituted AT III was 4.4 +/- 1.6 h in acute DIC and was 20.2 +/- 4.1 h when the patients were in a steady state.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7135359     DOI: 10.1016/0049-3848(82)90074-3

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

Review 1.  Recombinant natural anticoagulants: a review.

Authors:  P L Harper; J M Hermans; R W Carrell
Journal:  J R Soc Med       Date:  1992-07       Impact factor: 5.344

2.  Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study.

Authors:  F Baudo; T M Caimi; F de Cataldo; A Ravizza; S Arlati; G Casella; D Carugo; G Palareti; C Legnani; L Ridolfi; R Rossi; A D'Angelo; L Crippa; D Giudici; G Gallioli; A Wolfler; G Calori
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

Review 3.  Intensive care.

Authors:  S Sinclair; M Singer
Journal:  Postgrad Med J       Date:  1993-05       Impact factor: 2.401

4.  Anticoagulant therapy by continuous heparin-antithrombin III infusion in newborns with disseminated intravascular coagulation.

Authors:  R von Kries; H Stannigel; U Göbel
Journal:  Eur J Pediatr       Date:  1985-07       Impact factor: 3.183

5.  Purified fibronectin administration to patients with severe abdominal infections. A controlled clinical trial.

Authors:  P Lundsgaard-Hansen; J E Doran; E Rubli; E Papp; J J Morgenthaler; P Späth
Journal:  Ann Surg       Date:  1985-12       Impact factor: 12.969

6.  Plasma elimination of antithrombin III (heparin cofactor activity) is accelerated in term newborn infants.

Authors:  B Schmidt; U Wais; W Pringsheim; W Künzer
Journal:  Eur J Pediatr       Date:  1984-02       Impact factor: 3.183

Review 7.  Current drug treatment strategies for disseminated intravascular coagulation.

Authors:  E de Jonge; M Levi; C P Stoutenbeek; S J van Deventer
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

Review 8.  Coagulation inhibitor substitution during sepsis.

Authors:  F Fourrier; M Jourdain; A Tournois; C Caron; J Goudemand; C Chopin
Journal:  Intensive Care Med       Date:  1995-11       Impact factor: 17.440

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.